Gottlieb criticizes sponsors’ ‘continued reluctance’ to rethink clinical trials | FierceBiotech
Mar 15, 2019 @ 8:37

Outgoing FDA Commissioner Scott Gottlieb, M.D., has criticized the “continued reluctance” of sponsors and CROs to adopt innovative approaches to clinical trials. Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and…

Sourced through Scoop.it from: www.fiercebiotech.com

Leave a Reply